Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update
13. März 2023 07:30 ET
|
Gracell Biotechnologies Inc.
Plan to commence Phase 1b/2 clinical trial in US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) in the second quarter of 2023 after receipt of FDA...
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
14. Februar 2023 08:46 ET
|
Gracell Biotechnologies Inc.
SAN DIEGO, Calif., and SUZHOU, China and SHANGHAI, China, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global...
Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update
14. November 2022 07:15 ET
|
Gracell Biotechnologies Inc.
On track to submit IND filings in U.S. and China for GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) in the fourth quarter 2022First clinical data from ongoing...
Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update
15. August 2022 07:15 ET
|
Gracell Biotechnologies Inc.
Presented updated clinical data from an investigator-initiated trial (IIT) evaluating FasTCAR GC012F for the treatment of relapsed/refractory multiple myeloma (r/r MM) at ASCO and EHA 2022, which...
Gracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results and Provides Corporate Update
16. Mai 2022 07:30 ET
|
Gracell Biotechnologies Inc.
Presented early clinical data from a first-in-human Phase 1 investigator-initiated trial (IIT) of allogeneic TruUCAR candidate GC502 for relapsed/refractory B-cell acute lymphoblastic leukemia (r/r...
Gracell Biotechnologies to Participate in Three Investor Conferences in May
04. Mai 2022 08:30 ET
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 04, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company...
Gracell Biotechnologies to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
02. Mai 2022 08:00 ET
|
Gracell Biotechnologies Inc.
SAN DIEGO, Calif., and SUZHOU, China, May 02, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to...
Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2021
22. April 2022 17:00 ET
|
Gracell Biotechnologies Inc.
SAN DIEGO, Calif. and SUZHOU, China, April 22, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to...
Gracell Biotechnologies to Participate in Three Investor Conferences in April
29. März 2022 08:30 ET
|
Gracell Biotechnologies Inc.
PALO ALTO, Calif. and SUZHOU, China, March 29, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to...
Gracell Biotechnologies Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results and Provides Corporate Update
14. März 2022 07:30 ET
|
Gracell Biotechnologies Inc.
Plan to file U.S. IND for lead program FasTCAR-T GC012F for relapse and/or refractory multiple myeloma (RRMM) during second half of 2022Allogeneic TruUCAR-T GC502 currently being investigated in a...